It is known that in GBM patients (GBMPs), unlike patients with other types of malignant tumors of the central nervous system, the concentration of one of the cytoskeleton proteins—glial fibrillary acidic protein (GFAP)—is increased in the blood [5]. The gene discussed is GFAP; the disease is central nervous system cancer.